VIP, PACAP-38, BDNF and ADNP in NMDA-induced excitotoxicity in the rat retina

Barbara Teuchner, Andreas Dimmer, Christian Humpel, Albert Amberger, Reiner Fischer-Colbrie, J. Németh, James A. Waschek, Gerhard Kieselbach, Martina Kralinger, Eduard Schmid, Nikolaos Bechrakis, Josef Troger

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: To evaluate the effect of intravitreal injection of N-methyl-D-aspartate (NMDA) on brain-derived neurotrophic factor (BDNF), pituitary adenylate cyclase-activating peptide-38 (PACAP-38), vasoactive intestinal peptide (VIP) and the VIP-associated glial protein activity-dependent neuroprotective protein (ADNP) in the rat retina. These elements have well-documented neuroprotective properties and may thus be integrated in endogenous neuroprotective mechanisms in the retina which break down in NMDA excitotoxicity. Methods: A volume of 2 μl of 100 nmol NMDA was intravitreally injected into one eye of rats, the untreated eye served as a control. Time-dependent effects of NMDA on VIP, PACAP-38 and BDNF were detected by radioimmunoassay and ELISA, and the effect on the expression of VIP, PACAP-38 and ADNP was evaluated by quantitative RT-PCR 20 days after NMDA injection. Topical flunarizine served to find out whether the effect of NMDA is counteracted. Results: Compared to PACAP-38, VIP levels significantly decreased on days 1, 7, 14, 28 and 56 after NMDA injection indicating that VIPergic cells are more vulnerable than PACAP-38-expressing cells. The expression of VIP and ADNP but not of PACAP-38 was found to be reduced, and application of topical flunarizine counteracted the decrease of VIP. BDNF levels significantly increased after days 1 and 3. Conclusion: The early upregulation of BDNF seems to act neuroprotectively and leads to a delay of ganglion cell loss. Although there is no direct evidence, the decrease of VIP and ADNP - the consequence of the presence of NMDA receptors on these peptide-expressing cells - might contribute to the breakdown of endogenous neuroprotective mechanisms given that the decrease of the VIP-related ADNP runs in parallel with the decrease of VIP. Activating and maintaining these mechanisms must be the primary aim in the therapy of diseases with retinal neuronal degeneration.

Original languageEnglish
Pages (from-to)670-675
Number of pages6
JournalActa Ophthalmologica
Volume89
Issue number7
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Vasoactive Intestinal Peptide
Brain-Derived Neurotrophic Factor
N-Methylaspartate
Adenylyl Cyclases
Retina
Peptides
Proteins
Flunarizine
Retinal Degeneration
Intravitreal Injections
Injections
N-Methyl-D-Aspartate Receptors
Neuroglia
Ganglia
Radioimmunoassay
Up-Regulation
Enzyme-Linked Immunosorbent Assay
Polymerase Chain Reaction

Keywords

  • ADNP
  • BDNF
  • NMDA
  • PACAP-30
  • retina
  • VIP

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Teuchner, B., Dimmer, A., Humpel, C., Amberger, A., Fischer-Colbrie, R., Németh, J., ... Troger, J. (2011). VIP, PACAP-38, BDNF and ADNP in NMDA-induced excitotoxicity in the rat retina. Acta Ophthalmologica, 89(7), 670-675. https://doi.org/10.1111/j.1755-3768.2009.01828.x

VIP, PACAP-38, BDNF and ADNP in NMDA-induced excitotoxicity in the rat retina. / Teuchner, Barbara; Dimmer, Andreas; Humpel, Christian; Amberger, Albert; Fischer-Colbrie, Reiner; Németh, J.; Waschek, James A.; Kieselbach, Gerhard; Kralinger, Martina; Schmid, Eduard; Bechrakis, Nikolaos; Troger, Josef.

In: Acta Ophthalmologica, Vol. 89, No. 7, 11.2011, p. 670-675.

Research output: Contribution to journalArticle

Teuchner, B, Dimmer, A, Humpel, C, Amberger, A, Fischer-Colbrie, R, Németh, J, Waschek, JA, Kieselbach, G, Kralinger, M, Schmid, E, Bechrakis, N & Troger, J 2011, 'VIP, PACAP-38, BDNF and ADNP in NMDA-induced excitotoxicity in the rat retina', Acta Ophthalmologica, vol. 89, no. 7, pp. 670-675. https://doi.org/10.1111/j.1755-3768.2009.01828.x
Teuchner, Barbara ; Dimmer, Andreas ; Humpel, Christian ; Amberger, Albert ; Fischer-Colbrie, Reiner ; Németh, J. ; Waschek, James A. ; Kieselbach, Gerhard ; Kralinger, Martina ; Schmid, Eduard ; Bechrakis, Nikolaos ; Troger, Josef. / VIP, PACAP-38, BDNF and ADNP in NMDA-induced excitotoxicity in the rat retina. In: Acta Ophthalmologica. 2011 ; Vol. 89, No. 7. pp. 670-675.
@article{0a0069ab83b04a8499546bf65c354957,
title = "VIP, PACAP-38, BDNF and ADNP in NMDA-induced excitotoxicity in the rat retina",
abstract = "Purpose: To evaluate the effect of intravitreal injection of N-methyl-D-aspartate (NMDA) on brain-derived neurotrophic factor (BDNF), pituitary adenylate cyclase-activating peptide-38 (PACAP-38), vasoactive intestinal peptide (VIP) and the VIP-associated glial protein activity-dependent neuroprotective protein (ADNP) in the rat retina. These elements have well-documented neuroprotective properties and may thus be integrated in endogenous neuroprotective mechanisms in the retina which break down in NMDA excitotoxicity. Methods: A volume of 2 μl of 100 nmol NMDA was intravitreally injected into one eye of rats, the untreated eye served as a control. Time-dependent effects of NMDA on VIP, PACAP-38 and BDNF were detected by radioimmunoassay and ELISA, and the effect on the expression of VIP, PACAP-38 and ADNP was evaluated by quantitative RT-PCR 20 days after NMDA injection. Topical flunarizine served to find out whether the effect of NMDA is counteracted. Results: Compared to PACAP-38, VIP levels significantly decreased on days 1, 7, 14, 28 and 56 after NMDA injection indicating that VIPergic cells are more vulnerable than PACAP-38-expressing cells. The expression of VIP and ADNP but not of PACAP-38 was found to be reduced, and application of topical flunarizine counteracted the decrease of VIP. BDNF levels significantly increased after days 1 and 3. Conclusion: The early upregulation of BDNF seems to act neuroprotectively and leads to a delay of ganglion cell loss. Although there is no direct evidence, the decrease of VIP and ADNP - the consequence of the presence of NMDA receptors on these peptide-expressing cells - might contribute to the breakdown of endogenous neuroprotective mechanisms given that the decrease of the VIP-related ADNP runs in parallel with the decrease of VIP. Activating and maintaining these mechanisms must be the primary aim in the therapy of diseases with retinal neuronal degeneration.",
keywords = "ADNP, BDNF, NMDA, PACAP-30, retina, VIP",
author = "Barbara Teuchner and Andreas Dimmer and Christian Humpel and Albert Amberger and Reiner Fischer-Colbrie and J. N{\'e}meth and Waschek, {James A.} and Gerhard Kieselbach and Martina Kralinger and Eduard Schmid and Nikolaos Bechrakis and Josef Troger",
year = "2011",
month = "11",
doi = "10.1111/j.1755-3768.2009.01828.x",
language = "English",
volume = "89",
pages = "670--675",
journal = "Acta Ophthalmologica",
issn = "1755-375X",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - VIP, PACAP-38, BDNF and ADNP in NMDA-induced excitotoxicity in the rat retina

AU - Teuchner, Barbara

AU - Dimmer, Andreas

AU - Humpel, Christian

AU - Amberger, Albert

AU - Fischer-Colbrie, Reiner

AU - Németh, J.

AU - Waschek, James A.

AU - Kieselbach, Gerhard

AU - Kralinger, Martina

AU - Schmid, Eduard

AU - Bechrakis, Nikolaos

AU - Troger, Josef

PY - 2011/11

Y1 - 2011/11

N2 - Purpose: To evaluate the effect of intravitreal injection of N-methyl-D-aspartate (NMDA) on brain-derived neurotrophic factor (BDNF), pituitary adenylate cyclase-activating peptide-38 (PACAP-38), vasoactive intestinal peptide (VIP) and the VIP-associated glial protein activity-dependent neuroprotective protein (ADNP) in the rat retina. These elements have well-documented neuroprotective properties and may thus be integrated in endogenous neuroprotective mechanisms in the retina which break down in NMDA excitotoxicity. Methods: A volume of 2 μl of 100 nmol NMDA was intravitreally injected into one eye of rats, the untreated eye served as a control. Time-dependent effects of NMDA on VIP, PACAP-38 and BDNF were detected by radioimmunoassay and ELISA, and the effect on the expression of VIP, PACAP-38 and ADNP was evaluated by quantitative RT-PCR 20 days after NMDA injection. Topical flunarizine served to find out whether the effect of NMDA is counteracted. Results: Compared to PACAP-38, VIP levels significantly decreased on days 1, 7, 14, 28 and 56 after NMDA injection indicating that VIPergic cells are more vulnerable than PACAP-38-expressing cells. The expression of VIP and ADNP but not of PACAP-38 was found to be reduced, and application of topical flunarizine counteracted the decrease of VIP. BDNF levels significantly increased after days 1 and 3. Conclusion: The early upregulation of BDNF seems to act neuroprotectively and leads to a delay of ganglion cell loss. Although there is no direct evidence, the decrease of VIP and ADNP - the consequence of the presence of NMDA receptors on these peptide-expressing cells - might contribute to the breakdown of endogenous neuroprotective mechanisms given that the decrease of the VIP-related ADNP runs in parallel with the decrease of VIP. Activating and maintaining these mechanisms must be the primary aim in the therapy of diseases with retinal neuronal degeneration.

AB - Purpose: To evaluate the effect of intravitreal injection of N-methyl-D-aspartate (NMDA) on brain-derived neurotrophic factor (BDNF), pituitary adenylate cyclase-activating peptide-38 (PACAP-38), vasoactive intestinal peptide (VIP) and the VIP-associated glial protein activity-dependent neuroprotective protein (ADNP) in the rat retina. These elements have well-documented neuroprotective properties and may thus be integrated in endogenous neuroprotective mechanisms in the retina which break down in NMDA excitotoxicity. Methods: A volume of 2 μl of 100 nmol NMDA was intravitreally injected into one eye of rats, the untreated eye served as a control. Time-dependent effects of NMDA on VIP, PACAP-38 and BDNF were detected by radioimmunoassay and ELISA, and the effect on the expression of VIP, PACAP-38 and ADNP was evaluated by quantitative RT-PCR 20 days after NMDA injection. Topical flunarizine served to find out whether the effect of NMDA is counteracted. Results: Compared to PACAP-38, VIP levels significantly decreased on days 1, 7, 14, 28 and 56 after NMDA injection indicating that VIPergic cells are more vulnerable than PACAP-38-expressing cells. The expression of VIP and ADNP but not of PACAP-38 was found to be reduced, and application of topical flunarizine counteracted the decrease of VIP. BDNF levels significantly increased after days 1 and 3. Conclusion: The early upregulation of BDNF seems to act neuroprotectively and leads to a delay of ganglion cell loss. Although there is no direct evidence, the decrease of VIP and ADNP - the consequence of the presence of NMDA receptors on these peptide-expressing cells - might contribute to the breakdown of endogenous neuroprotective mechanisms given that the decrease of the VIP-related ADNP runs in parallel with the decrease of VIP. Activating and maintaining these mechanisms must be the primary aim in the therapy of diseases with retinal neuronal degeneration.

KW - ADNP

KW - BDNF

KW - NMDA

KW - PACAP-30

KW - retina

KW - VIP

UR - http://www.scopus.com/inward/record.url?scp=80155201152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80155201152&partnerID=8YFLogxK

U2 - 10.1111/j.1755-3768.2009.01828.x

DO - 10.1111/j.1755-3768.2009.01828.x

M3 - Article

C2 - 20064115

AN - SCOPUS:80155201152

VL - 89

SP - 670

EP - 675

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

SN - 1755-375X

IS - 7

ER -